GlaxoSmithKline is looking to fatten its drug pipeline through another venture capital investment with a $50 million commitment to a California fund.
The drug giant on Wednesday said it would invest in the $250 million Sanderling Biotech Venture Fund. The fund will be managed out of San Mateo, Calif.
The commitment is one of several made by GSK (NYS: GSK) to several funds focused on helping emerging and early-stage companies advancing potential drug candidates.
{iframe}http://wraltechwire.com/gsk-partner-stock-plunges-after-drug-failure/11961707/{/iframe}